Recursion Pharmaceuticals Inc.
RXRX | NASDAQ
$3.98
+$0.01 (+0.25%)
Sep 22, 2026, 10:30 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 | Q1 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 54.86M | 66.29M | 74.56M | 43.53M | 64.44M | 59.74M | 58.49M | 64.6M | 48.62M | 45.23M | 43.88M | 46.93M | 49.88M | 46.52M | 39.68M | 28.51M | 17.95M | 12.8M | 10M | 10.05M | 8.41M | 5.91M |
Cost of Revenue | 80.45M | 89.12M | 98.46M | 84.38M | 66.86M | 55.9M | 45.24M | 42.33M | 41.12M | 41.31M | 42.59M | 43.55M | 48.08M | 52.92M | 48.28M | 37.44M | 22.03M | 7.8M | n/a | n/a | n/a | n/a |
Gross Profit | -25.6M | -22.83M | -23.9M | -40.84M | -2.42M | 3.84M | 13.25M | 22.28M | 7.5M | 3.93M | 1.29M | 3.38M | 1.8M | -6.41M | -8.59M | -8.93M | -4.07M | 5M | 10M | 10.05M | 8.41M | 5.91M |
Operating Income | -544.01M | -585.27M | -648.13M | -723.57M | -649.72M | -574.03M | -479.01M | -394.17M | -395.36M | -376.54M | -350.06M | -312.11M | -275.14M | -259.61M | -245.73M | -249.71M | -233.53M | -208.27M | -182.78M | -143.4M | -119.47M | -96.76M |
Interest Income | 23.06M | 23.19M | 22.79M | 21.16M | 19.45M | 17.27M | 15.76M | 15.66M | 16.81M | 18.5M | 19.12M | 18.28M | 15.13M | 10.83M | 6.25M | 2.57M | 789K | 166K | 95K | 141K | 137K | 132K |
Pretax Income | -523.47M | -564.36M | -644.89M | -715.69M | -649.12M | -575.28M | -464.79M | -382.95M | -380.29M | -358.95M | -332.13M | -292.56M | -259.99M | -248.82M | -239.48M | -246.92M | -233.9M | -211.74M | -186.48M | -147.31M | -123.76M | -99.3M |
Net Income | -518.89M | -559.78M | -644.76M | -715.54M | -648.97M | -574.61M | -463.49M | -377.58M | -374.93M | -354.11M | -328.07M | -292.56M | -259.99M | -248.82M | -239.48M | -246.92M | -233.9M | -211.74M | -186.48M | -147.31M | -123.76M | -99.3M |
Selling & General & Admin | 151.41M | 156.53M | 176.59M | 220.12M | 216.25M | 201.43M | 178.18M | 131.46M | 122.9M | 119.36M | 110.82M | 100.2M | 90.49M | 83.4M | 81.6M | 80.96M | 77.16M | 69.82M | 57.68M | 46.06M | 37.33M | 28.63M |
Research & Development | 381.91M | 420.93M | 462.67M | 477.67M | 431.2M | 376.5M | 314.42M | 285.57M | 280.98M | 262.11M | 241.23M | 215.72M | 186.55M | 169.93M | 155.7M | 160.01M | 152.42M | 143.6M | 135.27M | 107.68M | 90.97M | 74.59M |
Other Expenses | -14.91M | -15.03M | -15.03M | -15.06M | -155K | -48K | -351K | -583K | -1.01M | -1M | -699K | -432K | -108K | -128K | -162K | -195K | -122K | -150K | -178K | -285K | -414K | -551K |
Operating Expenses | 518.41M | 562.44M | 624.23M | 682.72M | 647.3M | 577.87M | 492.26M | 416.44M | 402.86M | 380.46M | 351.35M | 315.49M | 276.94M | 253.2M | 237.13M | 240.78M | 229.46M | 213.27M | 192.78M | 153.45M | 127.88M | 102.67M |
Interest Expense | 1.49M | 1.66M | 1.82M | 2.43M | 2.15M | 2.06M | 1.57M | 993K | 465K | 97K | 96K | 83K | 71K | 59K | 54K | 43K | 250K | 2.74M | 2.97M | 3.2M | 3.38M | 1.31M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 598.86M | 651.56M | 722.69M | 767.1M | 714.16M | 633.78M | 537.49M | 458.77M | 443.98M | 421.77M | 393.94M | 359.04M | 325.01M | 306.13M | 285.41M | 278.21M | 251.49M | 221.07M | 192.78M | 153.45M | 127.88M | 102.67M |
Income Tax Expense | -4.58M | -4.58M | -135K | -148K | 16K | -507K | -1.13M | -5.2M | -5.36M | -4.84M | -4.06M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 532.46M | 529.3M | 526.72M | 446.99M | 417.36M | 402.77M | 336.04M | 282.58M | 242.2M | 236.02M | 233.16M | 214.33M | 201.42M | 191.62M | 185.67M | 173.44M | 172.21M | 170.69M | 169.37M | 168.53M | 168.43M | 168.32M |
Shares Outstanding (Diluted) | 532.46M | 529.3M | 526.72M | 446.99M | 417.36M | 402.77M | 336.04M | 282.58M | 242.2M | 236.02M | 233.16M | 214.33M | 201.42M | 191.62M | 185.67M | 173.44M | 172.21M | 170.69M | 169.37M | 168.53M | 168.43M | 168.32M |
EPS (Basic) | -1.04 | -1.20 | -1.48 | -1.80 | -1.78 | -1.77 | -1.66 | -1.53 | -1.62 | -1.60 | -1.53 | -1.44 | -1.35 | -1.35 | -1.36 | -1.43 | -1.37 | -1.25 | -1.10 | -0.87 | -0.73 | -0.59 |
EPS (Diluted) | -1.04 | -1.20 | -1.48 | -1.80 | -1.78 | -1.77 | -1.66 | -1.53 | -1.62 | -1.60 | -1.53 | -1.44 | -1.35 | -1.35 | -1.36 | -1.43 | -1.37 | -1.25 | -1.10 | -0.87 | -0.73 | -0.59 |
EBITDA | -444.45M | -479.48M | -560.21M | -636.92M | -583.64M | -524.77M | -426.72M | -350.86M | -348.35M | -330.81M | -307.63M | -272.42M | -244.45M | -236.05M | -227.67M | -235.76M | -223.09M | -198.9M | -174.76M | -136.32M | -114.16M | -93.09M |
EBIT | -522.81M | -563.53M | -643.91M | -714.1M | -646.97M | -573.22M | -463.22M | -381.96M | -379.83M | -358.86M | -332.03M | -292.48M | -259.92M | -248.77M | -239.42M | -246.9M | -233.67M | -209.03M | -183.53M | -144.11M | -120.38M | -97.99M |
Depreciation & Amortization | 78.36M | 84.04M | 83.7M | 77.17M | 63.33M | 48.45M | 36.49M | 31.1M | 31.48M | 28.05M | 24.4M | 20.06M | 15.47M | 12.72M | 11.76M | 11.12M | 10.57M | 10.11M | 8.75M | 7.79M | 6.21M | 4.91M |
Add to Watchlist
Select watchlists to add or remove RXRX